For these reasons, we speculate that our CCR4 IT and the bispecific IT will be more effective than FDA‐approved mogamulizumab for treatment of refractory or relapsed CTCL. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.